{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:44:03Z","timestamp":1792604643838,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10620-018-5149-6","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T12:32:20Z","timestamp":1528806740000},"page":"2155-2162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chemoprevention of Barrett\u2019s Esophagus and Esophageal Adenocarcinoma"],"prefix":"10.1007","volume":"63","author":[{"given":"Robert S.","family":"Bresalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"5149_CR1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.gastro.2015.04.053","volume":"149","author":"JH Rubenstein","year":"2015","unstructured":"Rubenstein JH, Shaheen NJ. Epidemiology, diagnosis, and management of esophageal adenocarcinoma. Gastroenterology. 2015;149:302\u2013317.","journal-title":"Gastroenterology"},{"key":"5149_CR2","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1053\/j.gastro.2005.08.053","volume":"129","author":"J Ronkainen","year":"2005","unstructured":"Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett\u2019s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825\u20131831.","journal-title":"Gastroenterology"},{"key":"5149_CR3","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/gutjnl-2011-300730","volume":"61","author":"TK Desai","year":"2012","unstructured":"Desai TK, Krishnan K, Samala N, Singh J, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett\u2019s esophagus: a meta-analysis. Gut. 2012;61:970\u2013976.","journal-title":"Gut"},{"key":"5149_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","volume":"111","author":"NJ Shaheen","year":"2016","unstructured":"Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: diagnosis and management of Barrett\u2019s esophagus. Am J Gastroenterol. 2016;111:30\u201350.","journal-title":"Am J Gastroenterol"},{"key":"5149_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","volume":"340","author":"J Lagergren","year":"1999","unstructured":"Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for for esophageal adenocarcinoma. N Engl J Med. 1999;340:825\u2013831.","journal-title":"N Engl J Med"},{"key":"5149_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.gtc.2015.02.010","volume":"44","author":"K Dunbar","year":"2015","unstructured":"Dunbar K, Souza RF, Spechler SJ. The effect of proton pump inhibitors on Barrett\u2019s esophagus. Gastroenterol Clin N Am. 2015;44:415\u2013424.","journal-title":"Gastroenterol Clin N Am"},{"key":"5149_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00535-017-1342-1","volume":"52","author":"RF Souza","year":"2017","unstructured":"Souza RF. Reflux esophagitis and its role in the pathogenesis of Barrett\u2019s esophagus. J Gastroenterol. 2017;52:767\u2013776.","journal-title":"J Gastroenterol"},{"key":"5149_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1053\/j.gastro.2011.11.019","volume":"142","author":"LM Liao","year":"2012","unstructured":"Liao LM, Vaughn TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442\u2013445.","journal-title":"Gastroenterology"},{"key":"5149_CR9","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1038\/bjc.2014.127","volume":"110","author":"S Zhang","year":"2014","unstructured":"Zhang S, Zhang XQ, Ding XW, et al. Cyclooxygense inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus:a meta-analysis. Br J Cancer. 2014;110:2378\u20132388.","journal-title":"Br J Cancer"},{"key":"5149_CR10","first-page":"442","volume":"2","author":"PC Galipeau","year":"2007","unstructured":"Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocercinoma. PLoS Med. 2007;2:442\u2013454.","journal-title":"PLoS Med"},{"key":"5149_CR11","first-page":"606","volume":"67","author":"X Huo","year":"2018","unstructured":"Huo X, Zhabng X, Yu C, et al. Aspirin prevents NF-\u039aB activation and CDX2 expression stimulated by acid and bile salts in oesophageal squamous cells of patients with Barrett\u2019s esophagus. Gut. 2018;67:606\u2013615.","journal-title":"Gut"},{"key":"5149_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/j.gastro.2012.06.044","volume":"143","author":"G Falk","year":"2012","unstructured":"Falk G, Buttar NS, Foster NR, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E2 in patients with Barrett\u2019s esophagus. Gastroenterology. 2012;143:917\u2013926.","journal-title":"Gastroenterology"},{"key":"5149_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10620-014-3349-2","volume":"60","author":"JL Schneider","year":"2015","unstructured":"Schneider JL, Zhao WK, Corley DA. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett\u2019s esophagus. Dig Dis Sci. 2015;60:436\u2013443. \n                    https:\/\/doi.org\/10.1007\/s10620-014-3349-2\n                    \n                  .","journal-title":"Dig Dis Sci"},{"key":"5149_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cgh.2012.02.031","volume":"10","author":"ZB Omer","year":"2012","unstructured":"Omer ZB, Ananthakrisnan AN, Nattinger KJ, et al. Aspirin protects against Barrett\u2019s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol. 2012;10:722\u2013727.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5149_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/ajg.2016.348","volume":"111","author":"AP Thrift","year":"2016","unstructured":"Thrift AP, Anderson LA, Murray LJ, et al. Nonsteroidal anti-inflammatory drug use is not associated with reduced risk of Barrett\u2019s esophagus. Am J Gastroenterol. 2016;111:1528\u20131535.","journal-title":"Am J Gastroenterol"},{"key":"5149_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1053\/j.gastro.2011.01.031","volume":"140","author":"SJ Spechler","year":"2011","unstructured":"Spechler SJ, Sharma P, Souza R, et al. American Gastroenterological Association medical position statement on the management of Barrett\u2019s esophagus. Gastroenterology. 2011;140:1084\u20131091.","journal-title":"Gastroenterology"},{"key":"5149_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/ajg.2015.322","volume":"111","author":"NJ Shaheen","year":"2016","unstructured":"Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline:diagnosis and management of Barrett\u2019s esophagus. Am J Gastroenterol. 2016;111:30\u201350.","journal-title":"Am J Gastroenterol"},{"key":"5149_CR18","first-page":"231","volume":"96","author":"DB Stairs","year":"2010","unstructured":"Stairs DB, Kong J, Lynch JP. Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia. Prog Mol Biol. 2010;96:231\u2013270.","journal-title":"Prog Mol Biol"},{"key":"5149_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/gut.51.3.316","volume":"51","author":"RE Fitzgerald","year":"2002","unstructured":"Fitzgerald RE, Abdalla S, Onuegbusi BA, et al. Inflammatory gradient in Barrett\u2019s oesophagus: implications for disease complications. Gut. 2002;51:316\u2013322.","journal-title":"Gut"},{"key":"5149_CR20","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/gut.2007.121244","volume":"c56","author":"S Song","year":"2007","unstructured":"Song S, Guha S, Liu K, Buttar NS, Bresdalier RS. Cox-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett\u2019s oesophagus and oesophageal carcinoma. Gut. 2007;c56:1512\u20131521.","journal-title":"Gut"},{"key":"5149_CR21","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","volume":"63","author":"S Singh","year":"2014","unstructured":"Singh S, Garg SK, Singh PP, et al. Acid-supressive medications and risk of oesophageal carcinoma in patients with Barrett\u2019s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229\u20131237.","journal-title":"Gut"},{"key":"5149_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cgh.2012.11.014","volume":"11","author":"F Kastelein","year":"2013","unstructured":"Kastelein F, Spaander MCW, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in pateitns with Barrett\u2019s esophagus. Clin Gastroenterol Hepatol. 2013;11:382\u2013388.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5149_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S1470-2045(09)70035-X","volume":"10","author":"J Cuzick","year":"2009","unstructured":"Cuzick J, Otto F. Brown PH, et.a l. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention:an international consensus statement. Lancet Oncol. 2009;10:501\u2013507.","journal-title":"Lancet Oncol"},{"key":"5149_CR24","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1053\/j.gastro.2010.02.045","volume":"138","author":"DM Nguyen","year":"2010","unstructured":"Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, stains, proton pump inhibitors and the risk of esophageal adenocarcinoma in patients with Barrett\u2019s esophagus. Gastroenterology. 2010;138:2260\u20132266.","journal-title":"Gastroenterology"},{"key":"5149_CR25","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1158\/0008-5472.CAN-05-4253","volume":"66","author":"LA Anderson","year":"2006","unstructured":"Anderson LA, Johnston BT, Watson RGP, et al. Nonsteroidal anti-inflammatory drugs and the esophageal-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975\u20134982.","journal-title":"Cancer Res"},{"key":"5149_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S1470-2045(05)70431-9","volume":"6","author":"TL Vaugn","year":"2005","unstructured":"Vaugn TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett\u2019s esophagus:a prospective study. Lancet Oncol. 2005;6:945\u2013952.","journal-title":"Lancet Oncol"},{"key":"5149_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1093\/jnci\/djk112","volume":"99","author":"EI Heath","year":"2007","unstructured":"Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett\u2019s esophagus with celecoxib: results of a randomized trial. JNCI. 2007;99:545\u2013557.","journal-title":"JNCI"},{"key":"5149_CR28","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","volume":"376","author":"PM Rothwell","year":"2010","unstructured":"Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20\u00a0year follow up of randomized trials. The Lancet. 2010;376:1741\u201317501.","journal-title":"The Lancet"},{"key":"5149_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrc.2016.4","volume":"16","author":"DA Drew","year":"2016","unstructured":"Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer. 2016;16:173\u2013186.","journal-title":"Nat Rev Cancer"},{"key":"5149_CR30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K, on behalf of the U.S. Preventive Services Task Force. Asprin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendations Statement. Ann Int Med. 2016;164:836\u2013845.","journal-title":"Ann Int Med"},{"key":"5149_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-540-69297-3_15","volume":"181","author":"D Das","year":"2009","unstructured":"Das D, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161\u2013169.","journal-title":"Recent Results Cancer Res"},{"key":"5149_CR32","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.gastro.2017.10.044","volume":"154","author":"AD Spence","year":"2018","unstructured":"Spence AD, Busby J, Johnston BT, et al. Low-dose aspirin does not increase survival in 2 independent population-based cohorts of patients with esophageal or gastric cancer. Gastroenterology. 2018;154:849\u2013860.","journal-title":"Gastroenterology"},{"key":"5149_CR33","doi-asserted-by":"publisher","first-page":"G129","DOI":"10.1152\/ajpgi.00085.2014","volume":"307","author":"S Peng","year":"2014","unstructured":"Peng S, Huo X, Rezaei D, et al. In Barrett\u2019s esophagus patients and cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids. Am J Physiol Gastrointest Liver Physiol. 2014;307:G129\u2013G139.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"5149_CR34","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1136\/gut.2007.121244","volume":"11","author":"S Song","year":"2007","unstructured":"Song S, Guha S, Liu K, Buttar NS, Bresalier RS. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signaling pathways in Barrett\u2019s oesophagus and oesophageal adenocarcinoma. Gut. 2007;11:1512\u20131521.","journal-title":"Gut"},{"key":"5149_CR35","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1158\/1940-6207.CAPR-14-0274-T","volume":"8","author":"AK Joe","year":"2015","unstructured":"Joe AK, Scnoll-Sussman F, Bresalier RS, et al. Phase Ib randomized, double-blnded, placebo-controlled, dose escalation study of polyphenon E in patients with Barrett\u2019s esophagus. Cancer Prev Res. 2015;8:1131\u20131137.","journal-title":"Cancer Prev Res"},{"key":"5149_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2011.04.061","volume":"141","author":"N Shaheen","year":"2011","unstructured":"Shaheen N, Overholt B, Sampliner R, et al. Durability of radiofrequency ablation in Barett\u2019s esophagus with dysplasia. Gastroenterology. 2011;141:460\u2013468.","journal-title":"Gastroenterology"},{"key":"5149_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/ajg.2012.413","volume":"108","author":"ES Orman","year":"2013","unstructured":"Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in pateints successfully treated for Barrettt\u2019s esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187\u2013195.","journal-title":"Am J Gastroenterol"},{"key":"5149_CR38","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.cgh.2014.04.034","volume":"12","author":"S Pasricha","year":"2014","unstructured":"Pasricha S, Buksiewicz WJ, Hathorn KE, et al. Durability and predictors of successful radiofrequency ablation for barrett\u2019s esophagus. Clin Gastroenterol Hepatol. 2014;12:1840\u20131847.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5149_CR39","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.gie.2014.12.029","volume":"81","author":"CC Cotton","year":"2015","unstructured":"Cotton CC, Wolf A, Pasricha S, et al. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett\u2019s esophagus :endoscopic findings and anatomic location. Gastrointest Endosc. 2015;81:1362\u20131369.","journal-title":"Gastrointest Endosc"},{"key":"5149_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/ajg.2016.451","volume":"112","author":"A Guthikonda","year":"2017","unstructured":"Guthikonda A, Cotton CC, Madanick RD, et al. Clinical outcomes following recurrence of intestinal metaplasia after successful treatment of Barrett\u2019s esophagus with radiofrequency ablation. Am J Gastroenterol. 2017;112:87\u201394.","journal-title":"Am J Gastroenterol"},{"key":"5149_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1053\/j.gastro.2017.05.044","volume":"153","author":"CC Cotton","year":"2017","unstructured":"Cotton CC, Wolf WA, Overholt BF, et al. Late recurrence of Barrett\u2019s esophagus after complete eradication of intestinal metaplasia is rare: final report from ablation in intestinal metaplasia containing dysplasia trial. Gastroenterology. 2017;153:681\u2013688.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5149-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5149-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5149-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T23:23:53Z","timestamp":1560295433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5149-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["5149"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5149-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]},"assertion":[{"value":"12 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author reports no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}